EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieOpen Access · CC BY 4.0

Dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda

Abel Kakuru iD, Jimmy Kizza iD, Miriam Aguti, Harriet Adrama, John Ategeka iD, Peter Olwoch, Miriam Nakalembe, Joaniter I Nankabirwa iD, Bishop Opira, Nida Ozarslan, Anju Ranjit, Erin Dela Cruz iD und 7 weitere

PLOS Medicine · 2025

DOI: 10.1371/journal.pmed.1004582 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Medicine, 2025. Verfasst von Abel Kakuru und 18 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Research Collaboration, Kampala, Uganda. Hauptthemen laut MEDLINE: Pyrimethamine, Sulfadoxine, Quinolines, Artemisinins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background To mitigate adverse consequences of malaria in pregnancy, the World Health Organization recommends intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine–pyrimethamine. However, the effectiveness of IPTp with sulfadoxine–pyrimethamine has been threatened by widespread Plasmodium falciparum resistance, especially in East and Southern Africa. For IPTp, dihydroartemisinin–piperaquine has shown superior antimalarial effects compared to sulfadoxine–pyrimethamine, but sulfadoxine–pyrimethamine has been associated with improved birth outcomes compared to dihydroartemisinin–piperaquine. We hypothesized that a combination of both dihydroartemisinin–piperaquine and sulfadoxine–pyrimethamine would provide superior birth outcomes compared to either drug alone. Methods and findings We conducted a double-blinded, randomized, controlled trial of 2,757 pregnant women in Uganda, where resistance of malaria parasites to sulfadoxine–pyrimethamine is widespread. Women were randomly assigned (1:1:1) to monthly IPTp with sulfadoxine–pyrimethamine, dihydroartemisinin–piperaquine, or dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine. The primary outcome was the risk of a composite adverse birth outcome defined as any of the following: spontaneous abortion, stillbirth, low birthweight (LBW, < 2,500 g), preterm delivery (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimethamineSulfadoxineQuinolinesArtemisininsAntimalarialsPregnancy Complications, ParasiticMalaria, FalciparumMalariaHumansFemalePregnancyDrug CombinationsDouble-Blind MethodUgandaAdultDrug Therapy, CombinationYoung AdultAdolescentInfant, NewbornPregnancy OutcomePiperazines

Substanzen

PyrimethamineSulfadoxineQuinolinesartenimolpiperaquineArtemisininsDrug Combinationsfanasil, pyrimethamine drug combinationAntimalarialsPiperazines

Autor:innen und Institutionen

  • Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Department of Community and Public Health, Busitema University, Tororo, Uganda.
  • School of Medicine, Makerere University, Kampala, Uganda.
  • Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California, United States of America.
  • Department of Medicine, University of California, San Francisco, California, United States of America.
  • Institute for Global Health Sciences, University of California, San Francisco, California, United States of America.

ORCID-Profile: Abel Kakuru, Jimmy Kizza, John Ategeka, Joaniter I Nankabirwa, Erin Dela Cruz, Michelle E Roh, Stephanie L Gaw, Prasanna Jagannathan, Moses R Kamya, Grant Dorsey

Förderung

  • NIAID NIH HHS
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Kakuru, A., Kizza, J., Aguti, M., Adrama, H., Ategeka, J., Olwoch, P., Nakalembe, M., Nankabirwa, J. I., Opira, B., Ozarslan, N., Ranjit, A., Dela Cruz, E., Clark, T. D., Roh, M. E., Gaw, S. L., Jagannathan, P., Rosenthal, P. J., Kamya, M. R., & Dorsey, G. (2025). Dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004582

Vancouver

Kakuru A, Kizza J, Aguti M, Adrama H, Ategeka J, Olwoch P, et al. Dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda. PLOS Medicine. 2025. doi:10.1371/journal.pmed.1004582

BibTeX
@article{Kakuru2025,
  author = {Kakuru, Abel and Kizza, Jimmy and Aguti, Miriam and Adrama, Harriet and Ategeka, John and Olwoch, Peter and Nakalembe, Miriam and Nankabirwa, Joaniter I and Opira, Bishop and Ozarslan, Nida and Ranjit, Anju and Dela Cruz, Erin and Clark, Tamara D and Roh, Michelle E and Gaw, Stephanie L and Jagannathan, Prasanna and Rosenthal, Philip J and Kamya, Moses R and Dorsey, Grant},
  title = {Dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda},
  journal = {PLOS Medicine},
  year = {2025},
  doi = {10.1371/journal.pmed.1004582}
}
Kostenlos starten →